Dystrophin as a therapeutic biomarker: Are we ignoring data from the past?

Neuromuscular Disorders

Volumn 24, Issue 6, 2014, Pages 463-466

  Wilton, Steve D ^a   Fletcher, Sue ^a   Flanigan, Kevin M ^b  

^a MURDOCH UNIVERSITY   (Australia)

^b NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

Biomarker; Duchenne muscular dystrophy; Dystrophin; Exon skipping

Indexed keywords

BIOLOGICAL MARKER; DYSTROPHIN; MICRORNA;

ARTICLE; BECKER MUSCULAR DYSTROPHY; DISEASE ASSOCIATION; DRUG TARGETING; DUCHENNE MUSCULAR DYSTROPHY; EXON SKIPPING; GENOTYPE PHENOTYPE CORRELATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; GENETICS; MALE; METABOLISM; MUSCULAR DYSTROPHY, DUCHENNE;

BIOLOGICAL MARKERS; DYSTROPHIN; HUMANS; MALE; MUSCULAR DYSTROPHY, DUCHENNE;

EID: 84901065563     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2014.03.007     Document Type: Article

References (36)

1. Nicholson L.V., Davison K., Johnson M.A., et al. Dystrophin in skeletal muscle. II. Immunoreactivity in patients with Xp21 muscular dystrophy. J Neurol Sci 1989, 94:137-146.
2. Uchino M., Araki S., Miike T., Teramoto H., Nakamura T., Yasutake T. Localization and characterization of dystrophin in muscle biopsy specimens from Duchenne muscular dystrophy and various neuromuscular disorders. Muscle Nerve 1989, 12:1009-1016.
3. Monaco A.P., Bertelson C.J., Liechti-Gallati S., Moser H., Kunkel L.M. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 1988, 2:90-95.
4. Koenig M., Beggs A.H., Moyer M., et al. The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet 1989, 45:498-506.
5. Emery A.E. The muscular dystrophies. Lancet 2002, 359:687-695.
6. Emery A.E. Muscular dystrophy into the new millennium. Neuromuscul Disord 2002, 12:343-349.
7. Aartsma-Rus A., Janson A.A., Kaman W.E., et al. Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. Hum Mol Genet 2003, 12:907-914.
8. van Deutekom J.C., Bremmer-Bout M., Janson A.A., et al. Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. Hum Mol Genet 2001, 10:1547-1554.
9. Wilton S.D., Fall A.M., Harding P.L., McClorey G., Coleman C., Fletcher S. Antisense oligonucleotide-induced exon skipping across the human dystrophin gene transcript. Mol Ther 2007, 15:1288-1296.
10. Fanin M., Freda M.P., Vitiello L., Danieli G.A., Pegoraro E., Angelini C. Duchenne phenotype with in-frame deletion removing major portion of dystrophin rod: threshold effect for deletion size?. Muscle Nerve 1996, 19:1154-1160.
11. Mendell J.R., Rodino-Klapac L.R., Sahenk Z., et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol 2013, 74:637-647.
12. Nicholson L.V., Johnson M.A., Bushby K.M., Gardner-Medwin D. Functional significance of dystrophin positive fibres in Duchenne muscular dystrophy. Arch Dis Child 1993, 68:632-636.
13. Gangopadhyay S.B., Sherratt T.G., Heckmatt J.Z., et al. Dystrophin in frameshift deletion patients with Becker muscular dystrophy. Am J Hum Genet 1992, 51:562-570.
14. Hodgson S., Hart K., Abbs S., et al. Correlation of clinical and deletion data in Duchenne and Becker muscular dystrophy. J Med Genet 1989, 26:682-693.
15. Chelly J., Gilgenkrantz H., Hugnot J.P., et al. Illegitimate transcription. Application to the analysis of truncated transcripts of the dystrophin gene in nonmuscle cultured cells from Duchenne and Becker patients. J Clin Invest 1991, 88:1161-1166.
16. Chelly J., Gilgenkrantz H., Lambert M., et al. Effect of dystrophin gene deletions on mRNA levels and processing in Duchenne and Becker muscular dystrophies. Cell 1990, 63:1239-1248.
17. Sharp P.S., Bye A.J.H., Wells D.J. Physiological characterization of muscle strength with variable levels of dystrophin restoration in mdx mice following local antisense therapy. Mol Ther 2011, 19:165-171.
18. Wells D.J., Wells K.E., Asante E.A., et al. Expression of human full-length and minidystrophin in transgenic mdx mice: implications for gene therapy of Duchenne muscular dystrophy. Hum Mol Genet 1995, 4:1245-1250.
19. Pellegrini C., Zulian A., Gualandi F., et al. Melanocytes - a novel tool to study mitochondrial dysfunction in Duchenne muscular dystrophy. J Cell Physiol 2013, 228:1323-1331.
20. Taylor L.E., Kaminoh Y.J., Rodesch C.K., Flanigan K.M. Quantification of dystrophin immunofluorescence in dystrophinopathy muscle specimens. Neuropathol Appl Neurobiol 2012, 38:591-601.
21. Arechavala-Gomeza V., Kinali M., Feng L., et al. Immunohistological intensity measurements as a tool to assess sarcolemma-associated protein expression. Neuropathol Appl Neurobiol 2010, 36:265-274.
22. Anthony K., Cirak S., Torelli S., et al. Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials. Brain 2011, 134:3547-3559.
23. Vignier N., Amor F., Fogel P., et al. Distinctive serum miRNA profile in mouse models of striated muscular pathologies. PLoS One 2013, 8:e55281.
24. Mizuno H., Nakamura A., Aoki Y., et al. Identification of muscle-specific microRNAs in serum of muscular dystrophy animal models: promising novel blood-based markers for muscular dystrophy. PLoS One 2011, 6:e18388.
25. Cacchiarelli D., Legnini I., Martone J., et al. MiRNAs as serum biomarkers for Duchenne muscular dystrophy. EMBO Mol Med 2011, 3:258-265.
26. Zaharieva I.T., Calissano M., Scoto M., et al. Dystromirs as serum biomarkers for monitoring the disease severity in Duchenne muscular dystrophy. PLoS One 2013, 8:e80263.
27. Mehan M.R., Ostroff R., Wilcox S.K., et al. Highly multiplexed proteomic platform for biomarker discovery, diagnostics, and therapeutics. Adv Exp Med Biol 2013, 735:283-300.
28. Wang C., Fang X., Lee C.S. Recent advances in capillary electrophoresis-based proteomic techniques for biomarker discovery. Methods Mol Biol 2013, 984:1-12.
29. McDermott J.E., Wang J., Mitchell H., et al. Challenges in biomarker discovery: combining expert insights with statistical analysis of complex Omics data. Exp Opin Med Diagn 2013, 7:37-51.
30. Monteiro M.S., Carvalho M., Bastos M.L., Guedes de Pinho P. Metabolomics analysis for biomarker discovery: advances and challenges. Curr Med Chem 2013, 20:257-271.
31. Wang I.M., Stone D.J., Nickle D., Loboda A., Puig O., Roberts C. Systems biology approach for new target and biomarker identification. Curr Top Microbiol Immunol 2013, 363:169-199.
32. Abdel-Salam E., Abdel-Meguid I., Korraa S.S. Markers of degeneration and regeneration in Duchenne muscular dystrophy. Acta Myol Myopath Cardiomyopath 2009, 28:94-100.
33. Nadarajah V.D., van Putten M., Chaouch A., et al. Serum matrix metalloproteinase-9 (MMP-9) as a biomarker for monitoring disease progression in Duchenne muscular dystrophy (DMD). Neuromuscul Disord 2011, 21:569-578.
34. Martins-Bach A.B., Bloise A.C., Vainzof M., Rahnamaye Rabbani S. Metabolic profile of dystrophic mdx mouse muscles analyzed with in vitro magnetic resonance spectroscopy (MRS). Magn Reson Imaging 2012, 30:1167-1176.
35. Hsieh T.J., Jaw T.S., Chuang H.Y., Jong Y.J., Liu G.C., Li C.W. Muscle metabolism in Duchenne muscular dystrophy assessed by in vivo proton magnetic resonance spectroscopy. J Comput Assist Tomogr 2009, 33:150-154.
36. Fletcher S., Adkin C.F., Meloni P., et al. Targeted exon skipping to address "leaky" mutations in the dystrophin gene. Mol Ther Nucleic Acids 2012, 1:e48.